Severe COVID-19 is associated with an increased subsequent risk of lung cancer. Viral pneumonia induces durable lung epigenetic imprinting that promotes tumor-supportive neutrophils and impairs T cell immunity, which is reversible with combined CXCR2 inhibition and PD-L1 blockade.

Li et al. developed a ferritin aggregation cell engager that helps CAR T cells better recognize and attack leukemia cells without re-engineering the CAR itself. This versatile platform overcomes antigen modulation and enables combination with chemotherapy.